TREVI THERAPEUTICS INC
NASDAQ: TRVI (Trevi Therapeutics, Inc.)
Kemas kini terakhir: 6 jam lalu14.95
-0.26 (-1.71%)
| Penutupan Terdahulu | 15.21 |
| Jumlah Dagangan | 2,138,487 |
| Harga / Buku (P/B) | 6.66 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.450 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.96% |
| Nisbah Semasa (MRQ) | 15.38 |
| Aliran Tunai Operasi (OCF TTM) | -41.27 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -24.53 M |
| Pulangan Atas Aset (ROA TTM) | -34.41% |
| Pulangan Atas Ekuiti (ROE TTM) | -55.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Trevi Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 79.20% |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HEFFERNAN MICHAEL THOMAS | - | 15.04 | -39,473 | -593,674 |
| Jumlah Keseluruhan Kuantiti Bersih | -39,473 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -593,674 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 15.04 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HEFFERNAN MICHAEL THOMAS | Pengarah | 15 Sep 2026 | Jual automatik (-) | 39,473 | 15.04 | 593,674 |
| HEFFERNAN MICHAEL THOMAS | Pengarah | 15 Sep 2026 | Pelaksanaan pilihan | 39,473 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |